Convatec: Accelerating in 3 Waves of Innovation

An Analysis of Convatec's New Accelerate Framework:

The transition from a structural turnaround phase to a scaling acceleration period represents a promising step for Convatec, particularly as the industry navigates a period of intensified regulatory scrutiny and shifting reimbursement landscapes in 2026. Convatec's announcement of its new "Accelerate" strategy at the April 2026 Capital Markets Day represents a formal conclusion to the FISBE (Focus, Innovate, Simplify, Build, Execute) program that defined the company’s operational philosophy from 2020 through 2025. For wound care industry insiders, this shift signifies a move away from remediating legacy inefficiencies and toward a growth model predicated on high-value innovation, digital integration, and aggressive market share acquisition in the chronic care space.

The broader context of this strategic announcement is framed by the company’s 2025 financial performance, which served as a validation of the FISBE 2.0 framework. Convatec reported a broad-based organic revenue growth of 6.4% (excluding the InnovaMatrix platform), alongside an adjusted operating margin expansion of 110 basis points to 22.3%. This performance occurred despite significant headwinds, including a paradigm shift in U.S. Medicare reimbursement for skin substitutes and persistent inflationary pressures affecting raw material costs. The Accelerate strategy addresses these external variables by upgrading medium-term organic revenue growth targets to 6-8% beginning in 2027 and setting a mid-20s adjusted operating margin target of 24-26% by the same year.

FISBE Turnaround Phase Complete

To understand the trajectory of the Accelerate strategy, let's examine the structural transformations achieved under FISBE. Between 2020 and 2025, Convatec underwent a multi-phase pivot designed to transform the organization into a focused leader in chronic care. In the pre-FISBE era (2016-2019), the company struggled with decentralized operations and a lack of innovation focus. FISBE 1.0 (2020-2022) established the foundations by simplifying the portfolio and disposing of peripheral activities, while FISBE 2.0 (2023-2025) delivered the transition towards sustainable and profitable growth.

One of the most notable achievements of the FISBE period was the rationalization of the product portfolio and manufacturing network. The organization reduced its General and Administrative (G&A) spend from 13% to below 7% of sales through the implementation of Convatec Business Service Centers and the centralization of procurement. In 2025 alone, productivity initiatives contributed 130 basis points to the operating margin, more than offsetting a 110-basis-point headwind from 3% inflation.

The "Focus" pillar of FISBE led the company to concentrate its resources on four global categories: Advanced Wound Care (AWC), Ostomy Care (OC), Continence Care (CC), and Infusion Care (IC). Management noted that these categories share significant technological synergies, as all products interact with the skin and rely on shared expertise in polymers, adhesives, and biomaterials. This synergy is critical for the Accelerate strategy, which seeks to leverage a "platform-driven architecture" to speed up the innovation cycle.

Advanced Wound Care: Navigating Technical and Regulatory Headwinds

The Advanced Wound Care segment remains a cornerstone of the Convatec portfolio, despite the volatility introduced by the U.S. Medicare reimbursement overhaul in 2026. In 2025, AWC (excluding InnovaMatrix) delivered 4.1% organic growth, driven by the rollout of ConvaFoam and the continued strength of the Aquacel Ag+ Extra franchise. The Accelerate strategy aims to push AWC toward high single-digit growth by 2028 through a focus on three distinct "Waves" of innovation.

The 2026 Medicare Reimbursement Shift for Biologics

The most significant event impacting the 2026 AWC landscape is the Centers for Medicare & Medicaid Services (CMS) Calendar Year 2026 Physician Fee Schedule (PFS) Final Rule. Convatec is prioritizing clinical evidence to defend the value proposition of InnovaMatrix; the organization is on track to publish results from its randomized controlled trials (RCTs) in 2026.

Innovation Pipelines: ConvaNiox and the Multi-modal Future

To offset the volatility in the biologics segment, Convatec is accelerating its "Wave 2" product launches, most notably ConvaNiox. ConvaNiox is an advanced wound dressing powered by a proprietary nitric oxide-generating technology, designed specifically for hard-to-heal wounds like diabetic foot ulcers (DFUs). Following EU and UK regulatory approval in 2025, ConvaNiox is expected to contribute to revenue growth from 2027 onward as it is rolled out across major European markets.

ConvaFoam, another key product in the AWC lineup, allows it to compete effectively in a segment that is increasingly dominated by hospitals seeking simplified, high-performance dressing choices.

Beyond Wound Care:

Infusion Care is Convatec's highest-growth division, delivering 12.5% organic growth in 2025 and targeted for sustained double-digit growth from 2027 under the Accelerate strategy. Growth is driven by automated insulin delivery partnerships with Medtronic and Tandem, and by expanding the Neria Guard infusion set into Parkinson's disease therapy via AbbVie's Vyalev. The business is on track to be the sole infusion set supplier to three major Parkinson's treatment providers by end of 2026. To support this, the Convatec is committing $135M–$165M in growth CapEx in 2026, with new production lines operational from 2027.

Ostomy Care and Continence Care provide a stable, recurring revenue base. OC returned to form with 4.5% organic growth in 2025 (aided by a new U.S. GPO contract unlocking 40,000 additional procedures annually) while CC grew 6.6%, led by the GentleCath Air for Women. A male variant launches in 2026, and the FeelClean platform targets UTI reduction as the next innovation frontier.

Underpinning all three categories is a growing digital health layer. The myConvatec platform uses AI image recognition to monitor peristomal skin and optimise product fit, reducing complications and readmissions. The me+ virtual nurse programme adds direct patient support. Together, they create switching costs and a care delivery model that competitors without comparable digital infrastructure will struggle to match.

Operational Excellence and the "IDEAL" Innovation Framework

The "Execution Excellence" pillar of the Accelerate strategy is powered by the "IDEAL" process, a proprietary framework for managing the innovation lifecycle. The framework emphasizes a 30% reduction in "cycle time" for product development, scaling, and launch.

1. Innovation (I): Identifying unmet customer needs through human-centered design.

2. Deliver (D): Ensuring "right first time" quality and on-time delivery.

3. Execution (E): Focused commercial execution and rapid global scale-up.

4. Accelerate (A): Utilizing platform architectures to iterate products across multiple categories.

5. Learn (L): Measuring patient loyalty via Net Promoter Scores (NPS) and reviews to inform future innovation.

This framework is critical for managing the "Wave 3" pipeline, which includes the next generation of ConvaNiox multimodal platforms and IoT-enabled infusion sets. By 2026, R&D spend has roughly doubled as a percentage of sales compared to 2019, supporting a record innovation pipeline of eight planned launches between 2026 and 2028.

Competitive Benchmarking: Convatec vs. Smith & Nephew and Coloplast

For wound care insiders, benchmarking Convatec’s Accelerate strategy against its primary rivals provides perspective on the company's relative positioning. Smith & Nephew, the second-largest global wound care player by revenue, announced its "RISE" strategy in December 2025. Like Accelerate, the RISE strategy (Reach, Innovate, Scale, Execute) focuses on accelerating innovation and improving trading margins to the mid-20s by 2028.

While Smith & Nephew has prioritized an "Efficiency Drive" that included headcount reductions in its Advanced Wound Management division, Convatec’s Accelerate plan is more focused on capacity expansion and reinvestment of strong cash flows.

However, Smith & Nephew has faced different challenges, including activist investor pressure from Elliott Investment Management and a more volatile performance in its Orthopaedics and Sports Medicine divisions. While Smith & Nephew has prioritized an "Efficiency Drive" that included headcount reductions in its Advanced Wound Management division, Convatec’s Accelerate plan is more focused on capacity expansion and reinvestment of strong cash flows.

Coloplast remains the dominant player in Ostomy Care with over 40% market share, primarily in Europe. Convatec’s Accelerate strategy challenges this dominance by targeting the U.S. market through its specialized sales force and biologics portfolio, which Coloplast currently seems to lack. The acquisition of the Granudacyn manufacturer by Mölnlycke in 2025 and Solventum's launch of the V.A.C. Peel and Place dressing in the UK in 2026 further highlight the intense competitive pressure in the AWC sector.

Global Market Context and Value-Based Procurement

The Accelerate strategy is also a response to the evolving macroeconomic and regional dynamics of the global wound care market, which is projected to grow at a CAGR of 5.8% to reach $42.5 billion by 2033. North America remains the largest market (holding a 40.8% share in 2026), but the Asia-Pacific region is witnessing the fastest growth due to an aging population and rising diabetes prevalence.

The UK NHS and the Shift to Outcomes

In the United Kingdom, the advanced wound care market is projected to reach $1.1 billion in 2026. The market is increasingly defined by a shift from cost-based procurement to value-based outcomes. Evidence from the NHS indicates that approximately 80-85% of wound care expenditure is driven by professional clinician time and hospitalizations, rather than the unit cost of dressings.

Convatec’s strategy aligns with this shift by generating clinical evidence that demonstrates the "total cost of care" benefits of its premium products. The NHS Supply Chain and regional procurement hubs are increasingly demanding robust health-economic justifications, which Convatec aims to provide through its RCTs and the myConvatec digital tracking tools.

Emerging Market Expansion

Convatec has significantly strengthened its distribution in China and the broader Asia-Pacific region, which now contributes over 1 percentage point to the category growth rate in some segments. By 2025, the company had expanded its ostomy and wound care presence in China, leveraging the rising healthcare infrastructure and growing awareness of advanced treatment options. This geographic diversification provides a hedge against regional reimbursement shocks, such as the 2026 CMS rule in the United States.

Financial Sustainability and Capital Allocation

The Accelerate strategy is underpinned by a disciplined capital allocation framework designed to create shareholder value while maintaining an investment-grade credit rating. The company targets a leverage ratio of approximately 2.0x Net Debt/EBITDA, which provides "dry powder" for selective M&A that fits the chronic care focus.

In 2025, Convatec returned $300 million to shareholders via share buybacks and maintained a progressive dividend policy with a 40% payout ratio. The strong cash conversion—c.100% equity cash conversion in 2025—is the "flywheel" that funds the record levels of growth CapEx required for the Accelerate phase.

Management noted that total CapEx will peak at around 9% of sales in 2026-2027 to build the Infusion Care capacity before falling back to a maintenance level of 5-7%. This front-loaded investment is a calculated move to capture share in the rapidly growing AID and Parkinson's therapy markets.

Strategic Outlook and Risks

While the Accelerate strategy positions Convatec for stronger returns, several risks could impede its progress. Intense competition in the Ostomy and Continence franchises from rivals like Coloplast and Hollister requires constant innovation to defend market share. Furthermore, regulatory headwinds such as the implementation of the EU Medical Device Regulation (MDR) have increased compliance costs and extended time-to-market for new iterations.

For wound care industry insiders, the "Accelerate" announcement represents a transition into a more mature operational phase. The company has moved beyond the "turnaround" narrative and is now focused on the execution of a high-complexity, high-margin innovation roadmap. By integrating digital health, clinical evidence, and aggressive capacity expansion, Convatec aims to solidify its position as a dominant force in the global chronic care market through 2030.

The evolution from FISBE to Accelerate is defined by three key takeaways for the sector:

1. Resilience through Diversification: The ability of the organization to absorb the InnovaMatrix impairment while maintaining double-digit EPS growth in 2025 demonstrates the strength of the four-category model.

2. Innovation as the Primary Lever: The move toward "Wave 3" products and the 30% reduction in development cycle times suggest a fundamental shift in how the company intends to outpace competitors.

3. Digital-Commercial Synergy: The integration of platforms like myConvatec and me+ into the core business model is a recognition that the future of chronic care lies in the intersection of physical medical devices and remote, data-driven patient support.

As the organization moves into the second half of 2026, the market will look for the first signs of the "Wave 2" revenue contribution and the publication of the InnovaMatrix RCTs as indicators that the Accelerate strategy is meeting its upgraded medium-term guidance.